June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery
Author Affiliations & Notes
  • Stuart Williams
    Envisia Therapeutics, Durham, NC
  • Sanjib Das
    Envisia Therapeutics, Durham, NC
  • Jeremy Hansen
    Envisia Therapeutics, Durham, NC
  • Janet Tully
    Envisia Therapeutics, Durham, NC
  • Melissa Hernandez
    Envisia Therapeutics, Durham, NC
  • Tyler Pegoraro
    Envisia Therapeutics, Durham, NC
  • Rozemarijn S Verhoeven
    Envisia Therapeutics, Durham, NC
  • Benjamin Maynor
    Envisia Therapeutics, Durham, NC
  • Benjamin Yerxa
    Envisia Therapeutics, Durham, NC
  • Footnotes
    Commercial Relationships Stuart Williams, Envisia Therapeutics (E); Sanjib Das, Envisia Therapeutics (E); Jeremy Hansen, Envisia Therapeutics (E); Janet Tully, Envisia Therapeutics (E); Melissa Hernandez, Envisia Therapeutics (E); Tyler Pegoraro, Envisia Therapeutics (E); Rozemarijn Verhoeven, Envisia Therapeutics (E); Benjamin Maynor, Envisia Therapeutics (E), Liquidia Technologies (E); Benjamin Yerxa, Envisia Therapeutics (E), Liquidia Technologies (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 5026. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Stuart Williams, Sanjib Das, Jeremy Hansen, Janet Tully, Melissa Hernandez, Tyler Pegoraro, Rozemarijn S Verhoeven, Benjamin Maynor, Benjamin Yerxa; Fabrication of Shape and Size Specific Nanoparticles for Ocular Drug Delivery. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):5026.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose
 

A major challenge in ophthalmic drug delivery is overcoming the rapid and effective clearance of drug from the target site(s) such as the ocular surface, subconjunctival space, or posterior segment. It has been shown that PLGA particles can act as biodegradable, sustained drug delivery systems for the eye, opening up the possibility for longer-lasting, more efficient dosage forms. However, traditional methods for PLGA nano- and microparticle preparation offer poor control over polydispersity and shape/size, which can result in sub-optimal particle reproducibility, product safety, and efficacy. Here, we demonstrate the utility of PRINT micromolding technology to produce monodisperse, shape-specific nano- and microparticles for use in ocular drug delivery. We encapsulate difluprednate in these particles to demonstrate high loadings and encapsulation efficiency.

 
Methods
 

Biodegradable nano- and microparticles loaded with difluprednate were fabricated using the PRINT™ technology. Particle morphology and size were determined with Scanning Electron Microscopy (SEM) and Dynamic light scattering (DLS). Drug retention in the particles was monitored at 37C in 1X PBS using an HPLC method.

 
Results
 

Polymer-difluprednate micro- and nanoparticles were fabricated with control over shape, size, charge, and drug loading (Figure 1). Particles were fabricated in a range of sizes from 200 nm up to 3 mm. Encapsulation efficiencies up to 95% for Difluprednate in microparticles were demonstrated. The ability of the particles to retain and release difluprednate over time was determined in a PBS pH=7.4 solution.

 
Conclusions
 

We have shown that PRINT micromolding can be used to reproducibly formulate polymer/difluprednate into particles with specific size and shape for ophthalmic drug delivery applications, with high loading and high drug encapsulation efficiency. These results demonstrate that PRINT technology is a versatile alternative to traditional methods for nano- and microparticle production that may offer superior control of particle size, loading or other properties.  

 
Figure 1. SEM images of (A) 200 nm (dia.) x 200 nm (h) (B) 1 micron ‘pollen’ shape and (C) 3mm (dia.) x 3 mm (h) polymer-difluprednate particles. Scale bars are 1 mm.
 
Figure 1. SEM images of (A) 200 nm (dia.) x 200 nm (h) (B) 1 micron ‘pollen’ shape and (C) 3mm (dia.) x 3 mm (h) polymer-difluprednate particles. Scale bars are 1 mm.

 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×